706TiP Phase III study assessing the “best of” radiotherapy compared to the “best of” surgery (trans-oral surgery (TOS)) in patients with T1-T2, N0-N1 oropharyngeal, supraglottic carcinoma and with T1, N0 hypopharyngeal carcinoma

Abstract

The current standard treatment for early stage OPSCC/SGSCC, and HPSCC is either surgery or radiotherapy, both with comparable high tumor control rates but with different side effect profiles and technical constraints. Treatment choice is generally based on institutional and patient preference but not on level 1 evidence with respect to functional recovery. Recently the introduction of techniques such as trans-oral laser and robotic surgery (TOS) and dysphagia optimized IMRT (DO-IMRT) have led to an improvement of treatment related side effects.